Table 2 Clinical characteristics and ART use among adherence study participants with matched ECS data available, and their representativeness with respect to women enrolled in the ECS
| Â | Adherence study | Â | |
|---|---|---|---|
|  | Antenatal survey and ECS (n=97) | Postnatal survey and ECS (n=44) | ECS enrolment only (n = 1596) |
Age at leaving full-time education | Â | Â | Â |
≤16 years | 1 (6%) | 2 (9%) | 204 (26%) |
17Â years or above | 15 (94%) | 20 (91%) | 595 (74%) |
History of injecting drug use | Â | Â | Â |
No | 87 (90%) | 35 (80%) | 1398 (88%) |
Yes | 10 (10%) | 9 (20%) | 191 (12%) |
History of pregnancy termination | Â | Â | Â |
0 | 40 (45%) | 14 (39%) | 540 (41%) |
1 | 27 (31%) | 8 (22%) | 338 (26%) |
2 or more | 21 (24%) | 14 (39%) | 435 (33%) |
Timing of HIV diagnosis | Â | Â | Â |
Before pregnancy | 44 (46%) | 23 (52%) | 693 (44%) |
1st/2nd trimesters | 48 (50%) | 21 (48%) | 736 (46%) |
3rd trimester/intrapartum | 4 (4%) | 0 | 159 (10%) |
Antenatal CD4 count (first in pregnancy) | Â | Â | Â |
≤350 cells/mm3 | 19 (28%) | 26 (76%) | 484 (39%) |
>350 cells/mm3 | 48 (72%) | 8 (24%) | 773 (61%) |
WHO stage | Â | Â | Â |
1-2 | 67 (78%) | 25 (61%) | 1160 (81%) |
3-4 | 19 (22%) | 16 (39%) | 269 (19%) |
Timing of ART initiation | Â | Â | Â |
Before conception | 7 (8%) | 7 (17%) | 95 (7%) |
1st/2nd trimester | 61 (66%) | 23 (56%) | 929 (65%) |
3rd trimester | 25 (27%) | 11 (27%) | 402 (28%) |
Antenatal ART regimen | Â | Â | Â |
Mono/dual | 11 (12%) | 3 (7%) | 314 (22%) |
cART | 83 (88%) | 39 (93%) | 1139 (78%) |
Median weeks on ART by completion of adherence survey | 13.7 (IQR 11.3, 17) | 43.7 (IQR 26.0, 54.9) | Â |